HEALTHMEDPAGE TODAY
Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide
Monotherapy with once-weekly retatrutide, an investigational triple hormone receptor agonist, improved glycemic control and body weight in adults with type 2 diabetes, as shown in the phase III TRANSCEND-T2D-1 trial. Up to 40% of patients achieved normal HbA1c levels.
Mentioned
Related Signal
Adjacent reporting
- Weekly diabetes jab shown to reduce blood-sugar levels and body weight
- New Weight Loss Drug Retatrutide Delivers Stunning Results
- Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
- New obesity treatment may help preserve muscle during weight loss
- New obesity drug from Lilly delivers major weight loss
- New weight-loss shot appears to outperform other obesity drugs on market